World Health Organization: HIV/AIDS fact sheet. 2018 12–February. 2018http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids

McMahon JH, Elliott JH, Bertagnolio S, Kubiak R and Jordan MR: Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: A systematic review. Bull World Health Organ. 91:377–385. 2013. View Article : Google Scholar : PubMed/NCBI

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, et al: Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 308:387–402. 2012. View Article : Google Scholar : PubMed/NCBI

Castronuovo D, Cacopardo B, Pinzone MR, Di Rosa M, Martellotta F, Schioppa O, Moreno S and Nunnari G: Bone disease in the setting of HIV infection: Update and review of the literature. Eur Rev Med Pharmacol Sci. 17:2413–2419. 2013.PubMed/NCBI

Scarpino M, Pinzone MR, Di Rosa M, Madeddu G, Focà E, Martellotta F, Schioppa O, Ceccarelli G, Celesia BM, d'Ettorre G, et al: Kidney disease in HIV-infected patients. Eur Rev Med Pharmacol Sci. 17:2660–2667. 2013.PubMed/NCBI

Pomerantz RJ and Nunnari G: HIV and GB virus C-can two viruses be better than one? N Engl J Med. 350:963–965. 2004. View Article : Google Scholar : PubMed/NCBI

Nunnari G, Coco C, Pinzone MR, Pavone P, Beretta M, Di Rosa M, Schnell M, Giorgio C and Cacopando B: The role of micronutrients in the diet of HIV-1-infected individuals. Front Biosci (Elite Ed). 4:2442–2456. 2012. View Article : Google Scholar : PubMed/NCBI

Pinzone MR, Berretta M, Cacopardo B and Nunnari G: Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol. 42:258–271. 2015. View Article : Google Scholar : PubMed/NCBI

Pinzone MR, Di Rosa M, Celesia BM, Condorelli F, Malaguarnera M, Madeddu G, Martellotta F, Castronuovo D, Gussio M, Coco C, et al: LPS and HIV gp120 modulate monocyte/macrophage CYP₂₇B1 and CYP₂₄A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci. 17:1938–1950. 2013.PubMed/NCBI

Pinzone MR, Cacopardo B, Condorelli F, Di Rosa M and Nunnari G: Sirtuin-1 and HIV-1: An overview. Curr Drug Targets. 14:648–652. 2013. View Article : Google Scholar : PubMed/NCBI

Capetti A, Landonio S, Meraviglia P, Di Biagio A, Lo Caputo S, Sterrantino G, Ammassari A, Menzaghi B, Franzetti M, De Socio GV, et al: 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: A multicentre Italian experience. PLoS One. 7:e392222012. View Article : Google Scholar : PubMed/NCBI

Visalli G, Paiardini M, Chirico C, Cervasi B, Currò M, Ferlazzo N, Bertuccio MP, Favaloro A, Pellicanò G, Sturniolo G, et al: Intracellular accumulation of cell cycle regulatory proteins and nucleolin re-localization are associated with pre-lethal ultrastructural lesions in circulating T lymphocytes: The HIV-induced cell cycle dysregulation revisited. Cell Cycle. 9:2130–2140. 2010. View Article : Google Scholar : PubMed/NCBI

Celesia BM, Nigro L, Pinzone MR, Coco C, La Rosa R, Bisicchia F, Mavilla S, Gussio M, Pellicanò G, Milioni V, et al: High prevalence of undiagnosed anxiety symptoms among HIV-positive individuals on cART: A cross-sectional study. Eur Rev Med Pharmacol Sci. 17:2040–2046. 2013.PubMed/NCBI

Visalli G, Bertuccio MP, Currò M, Pellicanò G, Sturniolo G, Carnevali A, Spataro P, Ientile R, Picerno I, Cavallari V, et al: Bioenergetics of T cell activation and death in HIV type 1 infection. AIDS Res Hum Retroviruses. 28:1110–1118. 2012. View Article : Google Scholar : PubMed/NCBI

Trovato M, Ruggeri RM, Sciacchitano S, Vicchio TM, Picerno I, Pellicanò G, Valenti A and Visalli G: Serum interleukin-6 levels are increased in HIV-infected patients that develop autoimmune disease during long-term follow-up. Immunobiology. 223:264–268. 2018. View Article : Google Scholar : PubMed/NCBI

D'Aleo F, Ceccarelli M, Venanzi Rullo E, Facciolà A, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Berretta M, et al: Hepatitis C-related hepatocellular carcinoma: Diagnostic and therapeutic management in HIV-patients. Eur Rev Med Pharmacol Sci. 21:5859–5867. 2017.PubMed/NCBI

Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, et al CISAI Study Group, : Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 12:e01792542017. View Article : Google Scholar : PubMed/NCBI

Facciolà A, Venanzi Rullo E, Ceccarelli M, D'Aleo F, Di Rosa M, Pinzone MR, Condorelli F, Visalli G, Picerno I, Fisichella R, et al: Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals. Eur Rev Med Pharmacol Sci. 21:5868–5869. 2017.PubMed/NCBI

Zanet E, Berretta M, Benedetto FD, Talamini R, Ballarin R, Nunnari G, Berretta S, Ridolfo A, Lleshi A, Zanghì A, et al: Pancreatic cancer in HIV-positive patients: A clinical case-control study. Pancreas. 41:1331–1335. 2012. View Article : Google Scholar : PubMed/NCBI

Nunnari G, Sullivan J, Xu Y, Nyirjesy P, Kulkosky J, Cavert W, Frank I and Pomerantz RJ: HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses. 21:714–718. 2005. View Article : Google Scholar : PubMed/NCBI

Nunnari G, Leto D, Sullivan J, Xu Y, Mehlman KE, Kulkosky J and Pomerantz RJ: Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses. 21:768–775. 2005. View Article : Google Scholar : PubMed/NCBI

Martellotta F, Berretta M, Cacopardo B, Fisichella R, Schioppa O, Zanghì A, Spartà D, Cappellani A, Talamini R, Izzi I, et al: Clinical presentation and outcome of squamous cell carcinoma of the anus in HIV-infected patients in the HAART-era: A GICAT experience. Eur Rev Med Pharmacol Sci. 16:1283–1291. 2012.PubMed/NCBI

Celesia BM, Castronuovo D, Pinzone MR, Bellissimo F, Mughini MT, Lupo G, Scarpino MR, Gussio M, Palermo F, Cosentino S, et al: Late presentation of HIV infection: Predictors of delayed diagnosis and survival in Eastern Sicily. Eur Rev Med Pharmacol Sci. 17:2218–2224. 2013.PubMed/NCBI

Bearz A, Vaccher E, Martellotta F, Spina M, Talamini R, Lleshi A, Cacopardo B, Nunnari G, Berretta M, Tirelli U, et al: Lung cancer in HIV positive patients: Τhe GICAT experience. Eur Rev Med Pharmacol Sci. 18:500–508. 2014.PubMed/NCBI

Capetti A, Meraviglia P, Landonio S, Sterrantino G, Di Biagio A, Lo Caputo S, Ammassari A, Menzaghi B, De Socio GV, Franzetti M, et al: Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: The SALIR-E study. Int J Antimicrob Agents. 43:189–194. 2014. View Article : Google Scholar : PubMed/NCBI

Nuvoli S, Caruana G, Babudieri S, Solinas P, Pellicanò G, Piras B, Fiore V, Bagella P, Calia GM, Yue M, et al: Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): A longitudinal DEXA study. Eur Rev Med Pharmacol Sci. 22:1852–1859. 2018.PubMed/NCBI

Ceccarelli M, Condorelli F, Venanzi Rullo E and Pellicanò GF: Editorial - Improving access and adherence to screening tests for cancers: A new, though old, challenge in the HIV epidemics. World Cancer Res J. 5:e10302018.

Ceccarelli M, Rullo EV, Facciolà A, Madeddu G, Cacopardo B, Taibi R, D'Aleo F, Pinzone MR, Picerno I, di Rosa M, et al: Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: A systematic review. Oncotarget. 9:17171–17180. 2018. View Article : Google Scholar : PubMed/NCBI

D'Aleo F, Cama BAV, Paolucci IA, et al: New and old assumptions on lung cancer in People Living with HIV. World Cancer Res J. 5:e10362018.

Visalli G, Facciolà A, D'Aleo F, Pinzone MR, Condorelli F, Nunnari G, Pellicano GF, Ceccarelli M and Venanzi Rullo E: HPV and urinary bladder carcinoma: A review of the literature. World Cancer Res J. 5:e10382018.

Pace MJ, Agosto L, Graf EH and O'Doherty U: HIV reservoirs and latency models. Virology. 411:344–354. 2011. View Article : Google Scholar : PubMed/NCBI

Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science. 280:1884–1888. 1998. View Article : Google Scholar : PubMed/NCBI

Briz V, Poveda E and Soriano V: HIV entry inhibitors: Mechanisms of action and resistance pathways. J Antimicrob Chemother. 57:619–627. 2006. View Article : Google Scholar : PubMed/NCBI

Ray S, Fatima Z and Saxena A: Drugs for AIDS. Mini Rev Med Chem. 10:147–161. 2010. View Article : Google Scholar : PubMed/NCBI

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, et al: Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis. 198:1345–1352. 2008. View Article : Google Scholar : PubMed/NCBI

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ and Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol. 75:579–588. 2001. View Article : Google Scholar : PubMed/NCBI

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, et al: Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 201:1481–1487. 2010. View Article : Google Scholar : PubMed/NCBI

CytoDyn Inc: An extension of protocol PRO 140_CD01 TS Study. ClinicalTrials.gov. Identifier: NCT02355184. First posted. February 4–2015, https://clinicaltrials.gov/ct2/show/NCT02355184

CytoDyn Inc: A randomized, double-blind, placebo-controlled trial, followed by single-arm treatment of PRO 140 in combination w/optimized background therapy in treatment-experienced HIV subjects (PRO 140). ClinicalTrials.gov. Identifier: NCT02483078. First posted. June 26–2015, https://clinicaltrials.gov/ct2/show/NCT02483078

Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M and Iizawa Y: TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 49:4584–4591. 2005. View Article : Google Scholar : PubMed/NCBI

Marier J-F, Trinh M, Pheng LH, Palleja SM and Martin DE: Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob Agents Chemother. 55:2768–2774. 2011. View Article : Google Scholar : PubMed/NCBI

Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay AL, Cade J, Enejosa J, Lefebvre E and Feinberg J: A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 30:869–878. 2016. View Article : Google Scholar : PubMed/NCBI

Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE and Palleja SM: Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 57:118–125. 2011. View Article : Google Scholar : PubMed/NCBI

Baba M, Miyake H, Wang X, Okamoto M and Takashima K: Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother. 51:707–715. 2007. View Article : Google Scholar : PubMed/NCBI

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F and Descamps D; ANRS CO5 HIV-2 Cohort, : Cenicriviroc, a novel CCR5 (R5) and CCR2 antagonist, shows in vitro activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 10:e01349042015. View Article : Google Scholar : PubMed/NCBI

Polianova MT, Ruscetti FW, Pert CB and Ruff MR: Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res. 67:83–92. 2005. View Article : Google Scholar : PubMed/NCBI

Pollicita M, Ruff MR, Pert CB, Polianova MT, Schols D, Ranazzi A, Perno CF and Aquaro S: Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells. Antivir Chem Chemother. 18:285–295. 2007. View Article : Google Scholar : PubMed/NCBI

Goodkin K, Vitiello B, Lyman WD, Asthana D, Atkinson JH, Heseltine PN, Molina R, Zheng W, Khamis I, Wilkie FL, et al: Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol. 12:178–189. 2006. View Article : Google Scholar : PubMed/NCBI

Agrawal L, Ducoudret O, Baichoo N, Laznicka M, Ruff M and Pert C: mDAPTA, a potent CCR5 receptor blocker, prevents viral recovery from CD8-depleted patient PBMCs with VL< 50 background. International AIDS Society. http://www.abstract-archive.org/Abstract/Share/4495

Polianova MT, Ruscetti FW, Pert CB, Tractenberg RE, Leoung G, Strang S and Ruff MR: Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides. 24:1093–1098. 2003. View Article : Google Scholar : PubMed/NCBI

Langley DR, Kimura SR, Sivaprakasam P, Zhou N, Dicker I, McAuliffe B, Wang T, Kadow JF, Meanwell NA and Krystal M: Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins. 83:331–350. 2015. View Article : Google Scholar : PubMed/NCBI

Nowicka-Sans B, Gong Y-F, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, et al: In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 56:3498–3507. 2012. View Article : Google Scholar : PubMed/NCBI

Li Z, Zhou N, Sun Y, Ray N, Lataillade M, Hanna GJ and Krystal M: Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother. 57:4172–4180. 2013. View Article : Google Scholar : PubMed/NCBI

Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Krystal M and Hanna GJ: Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 64:7–15. 2013. View Article : Google Scholar : PubMed/NCBI

Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, et al: Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 69:573–581. 2014. View Article : Google Scholar : PubMed/NCBI

Nettles RE, Schürmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, et al: Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 206:1002–1011. 2012. View Article : Google Scholar : PubMed/NCBI

Lalezari JP, Latiff GH, Brinson C, Echevarría J, Treviño-Pérez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, et al: Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 427–37. 2015. View Article : Google Scholar

Vii V Healthcare: Attachment inhibitor comparison in heavily treatment experienced patients. ClinicalTrials.gov. Identifier: NCT02362503. First posted. February 13–2015.https://clinicaltrials.gov/ct2/show/NCT02362503

Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, Huang M, Chen B, Liu B, Li X, et al: An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother. 54:191–196. 2010. View Article : Google Scholar : PubMed/NCBI

Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, Peng H, Wang X, Lu R, Wang C, et al: Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 13:82016. View Article : Google Scholar : PubMed/NCBI

Xie D: International congress of drug therapy in HIV infection 23–26 October 2016, Glasgow, UK. J Int AIDS Soc. 19:214872016.PubMed/NCBI

Yang W, Xiao Q, Wang D, Yao C and Yang J: Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results. Xenobiotica. 47:133–143. 2017. View Article : Google Scholar : PubMed/NCBI

Song R, Franco D, Kao C-Y, Yu F, Huang Y and Ho DD: Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol. 84:6935–6942. 2010. View Article : Google Scholar : PubMed/NCBI

Bruno CJ and Jacobson JM: Ibalizumab: An anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother. 65:1839–1841. 2010. View Article : Google Scholar : PubMed/NCBI

Merkenschlager M, Buck D, Beverley PC and Sattentau QJ: Functional epitope analysis of the human CD4 molecule. The MHC class II-dependent activation of resting T cells is inhibited by monoclonal antibodies to CD4 regardless whether or not they recognize epitopes involved in the binding of MHC class II or HIV gp120. J Immunol. 145:2839–2845. 1990.PubMed/NCBI

Delmonico FL, Knowles RW, Colvin RB, Cavender DE, Kawai T, Bedle M, Stroka D, Preffer FI, Haug C and Cosimi AB: Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies. Transplant Proc. 25:784–785. 1993.PubMed/NCBI

Reimann KA, Burkly LC, Burrus B, Waite BC, Lord CI and Letvin NL: In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res Hum Retroviruses. 9:199–207. 1993. View Article : Google Scholar : PubMed/NCBI

Moore JP, Sattentau QJ, Klasse PJ and Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol. 66:4784–4793. 1992.PubMed/NCBI

Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP and Lewis ST: Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 53:450–457. 2009. View Article : Google Scholar : PubMed/NCBI

Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, et al: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis. 189:286–291. 2004. View Article : Google Scholar : PubMed/NCBI

Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, Petropoulos CJ and Shafer RW: The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment. Antiviral Res. 92:484–487. 2011. View Article : Google Scholar : PubMed/NCBI

Zhang X-Q, Sorensen M, Fung M and Schooley RT: Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother. 50:2231–2233. 2006. View Article : Google Scholar : PubMed/NCBI

United Biomedicals: Study to evaluate safety and efficacy of UB421 antibody in HIV1 infected adults. ClinicalTrials.gov. Identifier: NCT01668043. First posted. August 17–2012.https://clinicaltrials.gov/ct2/show/NCT01668043

Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, et al ANRS VISCONTI study group, : Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9:e10032112013. View Article : Google Scholar : PubMed/NCBI